摘要:
An oral tobacco product (1) has a pouch (2) made of a nonwoven fabric, a tobacco mixture containing tobacco particles made from tobacco materials as a major ingredient, enclosed in the pouch (2), and a water-repellent area (30) formed on an inner surface of the pouch (2) to account for 50% of the entire inner surface of the pouch, the water-repellent area preventing permeation of water.
摘要:
The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof. The compounds represented by the formula (I) can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity and, therefore, is expected to be useful as a new type of a preventive or therapeutic agent for atherosclerosis or hyperlipidemia.
摘要:
The present invention relates to a compound of the formula [1′] wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.
摘要:
A gene silencing vector according to the present invention comprises a vector which includes a promoter, an enhancer sequence in the downstream of the promoter, and a gene encoding a potyvirus-origin coat protein in the downstream of the enhancer sequence, wherein in order to cause gene silencing of the specific target gene in a host plant, the vector is used with a specific target gene or a gene that is homologous to the target gene inserted in the vicinity of the gene encoding the coat protein.
摘要:
A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.
摘要翻译:其中R 1为式(I)的化合物为任选取代的芳基或任选取代的杂芳基; R 2是任选取代的C 1-6烷基,C 3-7环烷基等; R 3是氢原子,C 1-6烷基,羟基等; R 4是氢原子,C 1-6烷基等; R 5和R 6各自为C 1-6烷基等; R 7是任选取代的芳基或任选取代的杂芳基; X 1,X 2和X 3各自为C 1-6亚烷基等; 和X 4和X 5各自为单键,亚甲基等,其盐,其溶剂合物或其前药,以及含有 化合物,特别是钙受体拮抗剂和骨质疏松症的治疗剂。 本发明的化合物可用作伴有异常钙稳态或骨质疏松症,hypoparathyreosis,骨肉瘤,牙周病,骨折,骨关节炎,慢性类风湿性关节炎,佩吉特氏病,体液性高钙血症,常染色体显性低钙血症的疾病的治疗药物 喜欢。 此外,还提供了化合物的中间体。
摘要:
A goods arrangement system includes a goods storage arrangement apparatus 7000 capable of storing goods temporarily and discharging a specified number of goods at the same time. The goods storage arrangement apparatus 7000 consists of a gradient storage shelf 7774 made up of multiple gravity roller conveyors 7001, and arrangement conveyors 7002 associated with the stories of gravity roller conveyors. Unpackers 1000 and 2000 peel off outer flaps from each box (container) containing goods, and a flap opener 4000 opens up and down outer flaps on one of the sides of a box. A goods takeout apparatus 5000 takes out goods from a box. The taken-out goods are fed to the goods storage arrangement apparatus 7000 by a goods feeder 6000 based on a running cart 6034. In the goods storage arrangement apparatus 7000, the arrangement conveyors 6002 arrange multiple goods in a row substantially perpendicularly to the direction in which the arrangement conveyors run. A goods input apparatus 8000 puts the row of goods in an arrangement container C.
摘要:
A method of preparing (S)-.gamma.-hydroxymethyl-.alpha.,.beta.-butenolide includes the step of oxidizing a levoglucosenone with a peracid in an organic solvent. Peracetic acid, metha-chloroperbenzoic acid or magnesium monoperoxyphthalate hexahydrate can be used as the peracid. According to this method, an (S)-.gamma.-hydroxymethyl-.alpha.,.beta.-butenolide having high optical purity can be easily prepared from a levoglucosenone as a starting material at a high yield.
摘要:
The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone the gene of this protein. According to the present invention, an antimicrobial protein which can be obtained from a fraction of an aqueous extract of Lyophyllum shimeji precipitated by the ammonium sulfate precipitation method, has an antimicrobial activity at least against Rhizoctonia solani or Pyricularia oryzae, and shows the presence of components of about 70 kDa and/or about 65 kDa in molecular weight in the SDS-PAGE method. A gene encoding this protein and a method of using the same are provided.